Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4.

Fleseriu M, Pivonello R, Lacroix A, Biller BMK, Feelders R, Gadelha M, Bertherat J, Belaya Z, Piacentini A, Pedroncelli AM, Newell-Price J

Open source

DOI: 10.1093/ejendo/lvaf207
Published: 2025 Oct 30
Container: European journal of endocrinology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ejendo/lvaf207,
  title = {Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4.},
  author = {Fleseriu M and Pivonello R and Lacroix A and Biller BMK and Feelders R and Gadelha M and Bertherat J and Belaya Z and Piacentini A and Pedroncelli AM and Newell-Price J},
  year = {2025},
  journal = {European journal of endocrinology},
  doi = {10.1093/ejendo/lvaf207},
  url = {https://doi.org/10.1093/ejendo/lvaf207}
}

RIS

TY  - JOUR
TI  - Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4.
AU  - Fleseriu M
AU  - Pivonello R
AU  - Lacroix A
AU  - Biller BMK
AU  - Feelders R
AU  - Gadelha M
AU  - Bertherat J
AU  - Belaya Z
AU  - Piacentini A
AU  - Pedroncelli AM
AU  - Newell-Price J
PY  - 2025
JO  - European journal of endocrinology
DO  - 10.1093/ejendo/lvaf207
UR  - https://doi.org/10.1093/ejendo/lvaf207
ER  -

APA

M, F., R, P., A, L., BMK, B., R, F., M, G., J, B., Z, B., A, P., AM, P., & J, N. (2025). Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4.. European journal of endocrinology. https://doi.org/10.1093/ejendo/lvaf207

Source records

pubmed · retrieved 2026-09-26T10:09:38.413Z